The Food and Drug Administration on Thursday approved the antiviral drug remdesivir as a treatment for patients with COVID-19 who require hospitalization.
Given through an IV, remdesivir works to stop replication of SARS-CoV-2, the virus that causes COVID-19, according to the drug's manufacturer, California-based Gilead Sciences, Inc. Previously authorized by the FDA for emergency use to treat COVID-19, the drug is now the first and only approved COVID-19 treatment in the United States, Gilead said in a release.
“Since the beginning of the COVID-19 pandemic, Gilead has worked relentlessly to help find solutions to this global health crisis,” Gilead CEO Daniel O’Day said in a statement. “It is incredible to be in the position today, less than one year since the earliest case reports of the disease now known as COVID-19, of having an FDA-approved treatment in the U.S. that is available for all appropriate patients in need.
The drug cut the time to recovery by five days – from 15 days to 10 on average – in a large study led by the U.S. National Institutes of Health.
जन्नत की हकीकत, हमें भी पता है ग़ालिब दिल बहलाने को ये ख्याल अच्छा है
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Remdesivir to Treat COVID-19The pharmaceutical company Gilead Sciences announced that the FDA has approved the antiviral drug remdesivir for treating COVID-19, the company said Thursday in a news release. What you need to know:
Source: WebMD - 🏆 709. / 51 Read more »
Former FDA Commissioner Discusses Updates On COVID-19 Vaccine Research EffortsRachel Martin speaks with former Food and Drug Administration commissioner Dr. Mark McClellan about this week's FDA advisory panel on COVID-19 vaccine research.
Source: NPRHealth - 🏆 144. / 63 Read more »
FDA extends Covid-19 vaccine meeting to allow public inputThe FDA has added extra time to a daylong meeting Thursday of its vaccine advisers. The meeting will now include at least an hour and a half for public input, according to an agenda posted online. 2000: Vaccine skepticism is cool. 2010: Vaccine skepticism is anti-science. 2020: Vaccine skepticism is woke. Amazing to see the battle between big pharma creating the narrative of 'anti-vaxxers' being anti-science and Democrats claiming to be for science but anti-covid vaccine. Whatever they added are useless, America had a crazy selfish president, you just need to remove this Donald Trump, guaranteed America back to normal.
Source: CNN - 🏆 4. / 95 Read more »
How Will The U.S. Distribute COVID-19 Antibody Drugs If They Get FDA Approval?COVID-19 antibody drugs appear to be helping people avoid hospitalization. Tens of thousands of people a day could be candidates to take the drugs, but the scarce supply has to be rationed.
Source: NPRHealth - 🏆 144. / 63 Read more »
U.S. FDA panel to discuss COVID-19 vaccine trials after emergency authorizationA panel of independent experts to the U.S. health regulator will decide on the nature of clinical trials that coronavirus vaccines should go through after receiving U.S. emergency use authorization. what sucker is going first? understand coronavirus vaccine and the three vaccine candidates now. Coronavirus Vaccines Candidates works only under these conditions. That doesn’t sound right
Source: Reuters - 🏆 2. / 97 Read more »
Gilead's remdesivir gets U.S. FDA approval for hospitalized COVID-19 patientsThe U.S. Food and Drug Administration on Thursday approved Gilead Sciences Inc's antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States. There is a massacre going on in River State oyigbo They are moving from house to house slaughtering people oyigbokillings NIGERIABLEEDS And it doesn't work... But is still investigated ? and we heard that before ...
Source: Reuters - 🏆 2. / 97 Read more »